Rebecca Smith-Bindman, a professor at the University of California-San Francisco medical school, has spent well over a decade researching the disquieting risk that one of modern medicine’s most valuable tools, computerized tomography scans, can sometimes cause cancer. Smith-Bindman and like-minded colleagues have long pushed for federal policies aimed at improving safety for patients undergoing CT…
The federal Consumer Financial Protection Bureau has taken major steps to help people with medical debt in its nearly 14-year history. It issued rules barring medical debt from Americans’ credit reports and went after debt collectors who pressured customers to pay bills they didn’t owe. But in early February, the Trump administration moved to effectively…
The decline in cognitive health, especially that leading to Alzheimer’s and other brain diseases, is one of the most feared conditions by patients and their families. It’s also one of the most expensive. But if we can predict it early there are things we can do to prevent or ameliorate it. The issue has been…
Abarca Health is paying attention to specialty drugs, AI in healthcare, the impact of obesity-related conditions, and increased government regulations. The post 4 Prescription Drug Trends that are Top of Mind for One Abarca Exec appeared first on MedCity News.
Many experts – be they venture capitalists or private equity investprs – shared their advice to biotech entrepreneurs navigating a tough funding envornment. The post How Can Startups Navigate the Difficult Funding Environment appeared first on MedCity News.
Some healthcare providers have partnered with AI gun detection company ZeroEyes. The company adds its software to hospitals’ existing security camera systems to identify a gun before the shooter strikes. The post How One AI Company Is Tackling Gun Violence at Hospitals appeared first on MedCity News.
San Francisco-based Hinge Health grew its revenues by a third to nearly $400 million last year. Its customer base include more than 40 percent of Fortune 500 companies.
By KIM BELLARD A recent report from Moody’s Analytics, by chief economist Mark Zandi, had an eye-opening fact: the top 10% of earners in the U.S. – those who make $250,000 or more – now account for just shy (49.7%) of half of consumer spending. If that strikes you as unusual, you’re right. It is…
Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio in 2021. 2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. The post Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal appeared first on MedCity News.
Draft Continuing Resolution released on March 8 includes an extension of the telehealth flexibilities through September 30